Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.
Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…Long-term Safety of Medical Cannabis in Parkinson’s disease: a retrospective case-control study
Objective: This study aims to evaluate the effects of long-term treatment with medical cannabis (MC) on the course of Parkinson’s disease (PD), with a focus…GRIN2D is a cause of autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Diffusion-weighted imaging based free-water investigation in Parkinsonian disorders
Objective: To investigate free-water (FW) changes in Parkinson's disease (PD), Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Background: Various parkinsonian syndrome includes PD,…Dynamical modulations of low frequency deep brain stimulation on axial symptoms in Parkinson’s disease
Objective: First, we aimed to evaluate the optimal contact to address axial symptoms with low frequency deep brain stimulation (LFS). Second, we aimed to evaluate…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration
Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease
Objective: The Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (PD) initiative (EJS ACT-PD) aims to accelerate the identification of disease modifying treatment for…Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life
Objective: To describe the benefit of continuous subcutaneous apomorphine infusion (CSAI) for terminal care management in 7 PD patients. Background: There are currently no recommendations…
- « Previous Page
- 1
- …
- 295
- 296
- 297
- 298
- 299
- …
- 436
- Next Page »